drugset / Trial / NCT03133065
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study aimed to present our experience in treating recurrent HCV genotype 4 infection post living donor liver transplantation (LDLT) since introduction of the second generation direct acting antiviral drugs (DAAs) in Egypt.
Timeline
- Start
- 2014-09
- Primary completion
- 2016-12
- Completion
- 2017-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daclatasvir | Small molecule | 60 mg | Oral |
| Comparator | Ledipasvir | Small molecule | 90 mg | Oral |
| Comparator | Ribavirin | Small molecule | — | — |
| Comparator | Ritonavir | Other / unclassified | 50 mg | Oral |
| Comparator | Simeprevir | Small molecule | 150 mg | Oral |
| Comparator | Sofosbuvir | Small molecule | 400 mg | Oral |
| Comparator | ombitasvir | Small molecule | 12.5 mg | Oral |
| Comparator | paritaprevir | Small molecule | 75 mg | Oral |
Indications
No indication recorded.